FDA warned Mr. Lulu LLC of Claremont, California, that its OTC sunscreen drops were adulterated: no release testing, no identity testing, no batch records.
What happened
FDA inspected Mr. Lulu LLC's drug manufacturing facility at 815 West 10th Street, Claremont, California, from November 30 to December 9, 2022. Investigators found the firm shipped multiple batches of Mr. Lulu Sunscreen Drops SPF32 to the U.S. market without testing them for zinc oxide and titanium dioxide content, without testing incoming ingredients for identity, and without written batch records for batches made in March 2022 and November 2022. FDA called the firm's December 13, 2022 response to the inspection form (Form FDA 483, the list of observations from the inspection) inadequate, and said the product is adulterated, meaning it fails FDA's legal requirements.
What FDA found
The firm released batches of sunscreen without laboratory testing to confirm the identity and strength of the active ingredients, checking only scent, appearance and texture, and not writing the results down.
21 CFR 211.165(a)The firm did not test each incoming ingredient lot to confirm what it was, had no written supplier qualification procedure, and relied on supplier certificates of analysis without validating them.
21 CFR 211.84(d)(1) and (2)The firm used food-grade titanium dioxide as a drug ingredient without ensuring it met the United States Pharmacopeia (USP) standard, the official public quality standard for drugs.
Section 501(b) of the FD&C ActThe firm never validated its manufacturing process, never qualified its equipment, and never validated cleaning, and it admitted the mixer used to make the sunscreen is also used for personal use in the owner's kitchen.
21 CFR 211.100(a)The firm had no executed batch production records for the sunscreen batches it made and released.
21 CFR 211.188The firm had no quality control unit and no written procedures for deviations, complaints, recalls or stability, and it assigned no batch numbers, so finished product cannot be traced.
21 CFR 211.22
What FDA wants
FDA tells the firm to reply in writing within 15 working days describing corrections and how it will prevent recurrence, and to say whether it plans to resume making drugs at the facility before doing so. If it cannot finish within 15 working days, it must explain the delay and give a completion schedule.
Who should pay attention
- retailers and distributors that sold or stocked Mr. Lulu sunscreen drops
- small cosmetics and drug makers using shared or kitchen equipment
- brands that accept supplier certificates of analysis instead of testing incoming ingredients
This is a summary. Read the original letter on fda.gov.